You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Jean-Laurent Casanova aims to identify single-gene mutations that compromise the immunity of normally healthy individuals and lead to severe infectious disease.
The medium has been cleared for transporting samples potentially containing flu A and tuberculosis.
The exclusive two-way licensing deal also allows Akonni to commercialize Righton's molecular diagnostic tests outside of China.
In PLOS this week: small bowel adenocarcinoma mutation signatures, omic analysis of M. tuberculosis strains, and more.
The new funding will be used to develop a sample preparation module to concentrate bacteria and increase test sensitivity.
In Nature this week: genomes of two organisms that regenerate body parts, sea lamprey genome, and more.
The firm also announced the appointment of new board members as it heads toward commercialization of a portable MDx platform.
An international team analyzed almost 6,500 Mycobacterium tuberculosis isolates from around the world to find new and known resistance mutations.
The company's microchip-based technology will detect viral and bacterial genetic material using both isothermal amplification and electrochemical measurements.
By genotyping nearly 200 Mycobacterium bovis isolates, investigators saw signs of introductions of the pathogen, coupled with a long history in the region.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.